cbdMD financials
$0.4690+1.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 | FY20 Sep 30 | FY19 Sep 30 |
|---|---|---|---|---|---|---|---|
| Revenue | $19.2M | $19.5M | $24.2M | $35.4M | $44.5M | $41.9M | $23.7M |
| Gross profit | $12.0M | $12.0M | $15.0M | $22.3M | $30.0M | $26.4M | $14.5M |
| Gross margin | 62.4% | 61.6% | 62.0% | 63.1% | 67.4% | 63.0% | 61.4% |
| Operating income | -$2.2M | -$3.3M | -$22.3M | -$78.9M | -$26.3M | -$17.6M | -$47.8M |
| Net income | -$4.4M | -$7.7M | -$26.9M | -$74.1M | -$25.9M | $12.2M | -$50.4M |
| Net margin | −22.8% | −39.5% | −111.5% | −209.3% | −58.3% | 29.2% | −213.2% |
| Diluted EPS | $-1.09 | $-14.29 | $-13.32 | $-55.80 | $-21.15 | $12.60 | $-126.90 |
| EBITDA | -$1.0M | -$2.2M | -$7.5M | -$14.3M | -$17.4M | -$15.7M | -$14.1M |
| Operating cash flow | -$1.5M | -$352.8K | -$4.3M | -$15.0M | -$14.1M | -$10.6M | -$15.4M |
| Free cash flow | -$1.6M | -$542.8K | -$4.6M | -$15.7M | -$14.4M | -$12.0M | -$16.6M |
| Diluted shares | 4.0M | 0.5M | 2.0M | 1.3M | 1.2M | 1.0M | 0.4M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.3M | $2.5M | $1.8M | $6.7M | $26.4M | $14.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $1.0M | $1.0M | $276.5K |
| Total debt | $0.00 | $1.2M | $2.5K | $135.1K | $168.5K | $1.2M |
| Total assets | $10.4M | $10.6M | $16.2M | $40.8M | $124.9M | $110.8M |
| Total liabilities | $3.2M | $8.6M | $7.2M | $9.4M | $21.7M | $31.7M |
| Shareholders' equity | $7.2M | $2.0M | $9.0M | $31.4M | $103.1M | $79.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology